Photronics reported weaker-than-expected Q2 2026 results with revenue down year-over-year and operating margins dropping from 26.4% to 20.1%. The company cited delays in product launches due to high fab utilization, memory supply issues, cost pressures, and geopolitical uncertainty. Following the earnings release, Photronics' stock fell 36.4%, prompting an investigation by Pomerantz LLP into possible securities fraud or unlawful practices by the company and its executives. Investors impacted by the stock drop are encouraged to contact the law firm for potential class action participation.
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
BlackRock reported quarterly earnings per share of $13.91, surpassing analyst estimates of $12.69, and revenue of $7.08 billion, exceeding expectations of $6.73 billion. The company’s assets under management reached a record $15.3 trillion, a 22% inc...
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
